Company: ALGN
Filing Date: 2025-03-27
Form Type: PRE 14A
Source: 0001097149-25-000016
Chunk: 1

Company: ALIGN TECHNOLOGY INC
Filing Date: 2025-03-27
Form: PRE 14A
Chunk 1
---
 statements may contain words such as “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “may,” “opportunity,” “plan,” “project,” “should,” “strategy,” “will,” “will be,” “will continue,” “will likely result,” “would” and similar expressions.

These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in particular, the risks discussed in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on February 28, 2025.

We undertake no obligation to revise or update these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Unless otherwise expressly stated or context requires otherwise, information in this proxy statement is as of April [__], 2025.

<div align='center'>iii</div>

|                                                                                                                                                                                                                                                |     | Letter to Our Stockholders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| “Together, with our customers, we are transforming the way doctors deliver and patients experience digital orthodontics and restorative dentistry, expanding the adoption of clear aligners, and creating lasting value for all stakeholders.” 
 •Major milestones:20 millionInvisalign®patients treated—including over5.6 millionteens and kids—over271 thousandactive Invisalign®trained practitioners,andover2 billionclear aligners manufactured worldwide                                  
 •FY 2024 Total Revenues of$4.0 billion                                                                                                                                                                                                         
 •FY 2024 Operating Margin of15.2%, or21.8%on a non-GAAP basis                                                                                                                                                                                  
 •FY 2024 Diluted Net Income per share of$5.62, or$9.33on a non-GAAP basis                                                                                                                                                                      
 •Repurchased$353million of Align common stock during 2024                                                                                                                                                                                      |     | April [__], 2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 Dear Stockholders,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 As I write this letter, we have just wrapped up a global clinical symposium with our most engaged orth